Every year, more than half a million people in the world are diagnosed with malignant CNS tumors. Unfortunately, despite certain advances in medicine, a third of them die within the first year of diagnosis. All this dictates the need to search for new diagnostic methods and targets for personalized, targeted therapy. One of them can be a protein-based agent called RAS70, developed by the team of the Translational Oncology Laboratory of the WCRC for Personalized Medicine.
It can selectively accumulate in cancer cells due to conjugation to heat shock protein Hsp70, which is only localized on tumor cells. Because of this ability, the RAS70 agent can target cancer cells exclusively while sparing healthy cells.
For more, read the news of WCRC for Personalized Medicine.